Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Overview | Financials
Company Name Supernus Pharmaceuticals, Inc.
Symbol SUPN
Currency USD
Price 33.84
Market Cap 1,864,766,736
Dividend Yield 0%
52-week-range 21.99 - 35.44
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Jack A. Khattar
Website https://www.supernus.com

An error occurred while fetching data.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis

Related Stocks

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

11.03 USD

Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

111.58 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

38.47 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

10.98 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

184.19 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

3.38 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

41.59 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

126.37 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

101.14 USD

Financials

Numbers are in millions USD

Numbers are in millions USD